I originally thought the same as you on this feature but the discussion today changed my view on the importance of this and now believe this to be a major differentiation. AGN apparently had to jump through hoops when the hurricanes hit key markets (Florida and Texas) to help out providers. Also- shipments are expensive as the have to be iced with temperature recording devices which were significant SG&A items. Internationally this may be important as well. Providers are going to care about this and I now believe this is going to be a RT002 success driver.
I don't worry about Xeomin and Dysport as they are immaterial IMO if RVNC gets 6 mos. The key is Botox doesn't have this feature and it is important to doctors.
Overall I'm very encouraged by the way Revance presented their case today and am going to add to my already out sized position.
Market Data 
Markets 
AI
